title: Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.
abstract: OBJECTIVE
  Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer cell types, including small cell lung cancer. We conducted a first-in-human, first-in-class phase I clinical trial of this agent in patients with cancers with neuroendocrine features, including small cell lung cancer.
  
  
  METHODS
  Clinical evaluation of single intravenous doses in patients with cancers with neuroendocrine features was performed across five log-increments from 10(7) to 10(11) vp/kg. Toxicity, viral titers and clearance, neutralizing antibody development, and tumor response were assessed.
  
  
  RESULTS
  A total of 30 patients were treated with SVV-001, including six with small cell carcinoma at the lowest dose of 10(7) vp/kg. SVV-001 was well tolerated, with no dose-limiting toxicities observed in any dose cohort. Viral clearance was documented in all subjects and correlated temporally with development of antiviral antibodies. Evidence of in vivo intratumoral viral replication was observed among patients with small cell carcinoma, with peak viral titers estimated to be >10(3)-fold higher than the administered dose. One patient with previously progressive chemorefractory small cell lung cancer remained progression-free for 10 months after SVV-001 administration, and is alive over 3 years after treatment.
  
  
  CONCLUSIONS
  Intravenous SVV-001 administration in patients is well tolerated at doses up to 10(11) vp/kg, with predictable viral clearance kinetics, intratumoral viral replication, and evidence of antitumor activity in patients with small cell lung cancer. Phase II clinical evaluation in small cell lung cancer is warranted, and has been initiated.
authors.affiliation: Johns Hopkins University, Baltimore, Maryland, USA. rudin@jhmi.edu
authors.forename: Charles M
authors.initials: CM
authors.lastname: Rudin
authors.forename: John T
authors.initials: JT
authors.lastname: Poirier
authors.forename: Neil N
authors.initials: NN
authors.lastname: Senzer
authors.forename: Joseph
authors.initials: J
authors.lastname: Stephenson
authors.forename: David
authors.initials: D
authors.lastname: Loesch
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Burroughs
authors.forename: P Seshidhar
authors.initials: PS
authors.lastname: Reddy
authors.forename: Christine L
authors.initials: CL
authors.lastname: Hann
authors.forename: Paul L
authors.initials: PL
authors.lastname: Hallenbeck
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D050130:Oncolytic Virotherapy; D010849:Picornaviridae; D055752:Small Cell Lung Carcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy* / Q000821:virology; D016896:Treatment Outcome; D019562:Viral Load